Treatment with pegylated interferon in hepatitis C
Cernadas C, Pichon Riviere A, Garcia Marti S
Record ID 32005000650
Spanish
Authors' objectives:
The aim of this report was to investigate treatment with pegylated interferon in hepatitis C
Authors' results and conclusions:
In eleven clinical trials comparing the effectiveness of pegylated interferon vs standard treatment (alpha interferon + rivabirin), it was observed that pegylated interferon has more capacity to obtain a sustained viral response (defined as the absence of viral RNA, 6 months after the treatment is completed). In general, Pegylated interferon can increase in approximately 10% the number of patients with sustained viral response (approximately 55% of success vs 45% with the standard treatment). This new Interferon is also administered together with ribavirin.
Authors' recommendations:
It is important to bear in mind that the results from the reports published refer, in general, to intermediate end-points (such as viral load, transaminase normalization, etc.), though important, it has not been clearly studied how these intermediate results impact on significant clinical findings such as decrease in mortality, hepatocellular carcinoma or cirrhosis.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Antiviral Agents
- Hepatitis C, Chronic
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.